Management of Sleep Disturbances and Psychosis in Parkinson's Disease with Early Dementia

Sleeping Aid Recommendations

The American Academy of Sleep Medicine recommends immediate-release melatonin starting at 3 mg at bedtime, with dose escalation by 3 mg increments up to 15 mg as needed, for sleep disturbances in Parkinson's patients with emerging dementia 1, 2, 3
Melatonin has a favorable safety profile with only mild sedative properties and minimal risk of falls, cognitive worsening, or motor deterioration, making it a preferred choice for this population 2, 3, 4
The American Academy of Sleep Medicine conditionally recommends melatonin for secondary REM sleep behavior disorder (RBD) in Parkinson's disease, which commonly coexists with sleep disturbances in PD patients 1, 2, 3

Rivastigmine (cholinesterase inhibitor) may provide dual benefit for both dementia and psychotic symptoms in PD, and is FDA-approved for PD dementia 1, 2, 6
The FDA has issued a black box warning regarding increased risk of death when antipsychotics are used for dementia-related behavioral disturbances 6

Implement bright light therapy at 2,500-5,000 lux for 1-2 hours daily between 9:00-11:00 AM to regulate circadian rhythms 4, 5
Maximize daytime sunlight exposure (at least 30 minutes daily) while reducing nighttime light and noise 4, 5
Remove potentially dangerous objects from the bedroom for safety, particularly important given risk of RBD-related injury 4, 7
Establish structured bedtime routine and increase physical/social activities during daytime hours to consolidate sleep-wake cycles 4, 5